The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Following the demerger of ITC Hotels from ITC Ltd, Nuvama expects an outflow of approximately $180 million due to the ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

Niftys earnings per share (EPS) expected by a modest 2 per cent year-on-year (YoY) in the third quarter of FY25, according to ...

SBI Card shares rose 5% on January 6 after brokerages Nomura and Nuvama upgraded the stock to ’buy’. Nomura set a target ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

Media companies expected to report muted Q3FY25 results with some segments showing growth, but overall performance remains ...

Reliance Industries Limited (RIL) is structured into three primary business divisions: oil-to-chemicals (O2C), encompassing ...